Fair points mate but cap raises are often a fact of life with clinical stage biotechs anyway. So knowing that context idk if it's a downside of CHM specifically or just being involved in this space in general.
valuation thoughts, page-124
-
- There are more pages in this discussion • 257 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.18M | |||
| Open | High | Low | Value | Volume |
| 1.6¢ | 1.7¢ | 1.6¢ | $11.35K | 702.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 1886263 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 168006 | 2 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| CHM (ASX) Chart |